Models of relapse of experimental visceral leishmaniasis

Journal of Infectious Diseases

Volumn 173, Issue 4, 1996, Pages 1041-1043

  Murray, Henry W ^a   Hariprashad, June ^b   Fichtl, Richard E ^b  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNE DEFICIENCY; IMMUNITY; LEISHMANIA DONOVANI; MOUSE; NONHUMAN; PRIORITY JOURNAL; RELAPSE; T LYMPHOCYTE; VISCERAL LEISHMANIASIS;

EID: 0030029501     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/173.4.1041     Document Type: Article

References (15)

1. Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992;46:296-306.
2. Holaday BJ, Pompeu M, Evans T, et al. Correlates of Leishmania-specific immunity in the clinical spectrum of infection with Leishmania chagasi. J Infect Dis 1993;167:411-7.
3. Olliaro PL, Bryceson ADM. Practical progress and new drugs for changing patterns of leishmaniasis. Parasitol Today 1993;9:323-8.
4. Peters BS, Fish D, Golden R, Evans DA, Bryceson ADM, Pinching AJ. Visceral leishmaniasis in HIV infection and AIDS: clinical features and response to therapy. Q J Med 1990;77:1101-11.
5. Fernandez-Guerrero M, Aguado J, Buzon L, et al. Visceral leishmaniasis in immunocompromised hosts. Am J Med 1987;83:1098-102.
6. + cells in experimental visceral leishmaniasis. J Immunol 1988;140:3971-5.
7. Pearson RD, deSousa AQ. Leishmania species: visceral (kala-azar), cutaneous, and mucosal leishmaniasis. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practices of infectious diseases. New York: Churchill Livingston, 1995:2428-42.
8. Murray HW, Squires KE, Miralles GD, et al. Acquired resistance and granuloma formation in experimental visceral leishmaniasis. Differential T cell and lymphokine roles in initial versus established immunity. J Immunol 1992;148:1858-63.
9. Tumang M, Keogh C, Moldawer L, Helfgott DH, Hariprashad J, Murray HW. Role and effect of tumor necrosis factor-α in experimental visceral leishmaniasis. J Immunol 1994;153:768-74.
10. Murray HW, Hariprashad J. Interleukin 12 is effective treatment for an established systemic intracellular infection: experimental visceral leishmaniasis. J Exp Med 1995;181:387-91.
11. Murray HW, Hariprashad J, Fichtl R. Treatment of experimental visceral leishmaniasis in a T cell-deficient host: response to amphotericin B and pentamidine. Antimicrob Agents Chemother 1993;37:1504-5.
12. Murray HW, Oca MJ, Granger AM, Schreiber RD. Successful response to chemotherapy in experiemental visceral leishmaniasis: requirement for T cells and effect of lymphokines. J Clin Invest 1989;83:1253-9.
13. Mishra M, Biswas UK, Jha AM, Khan AB. Amphotericin B versus sodium stibogluconate in the first-line treatment of Indian kala-azar. Lancet 1994;344:1599-600.
14. Davidson RN, DiMartino L, Gradoni L, et al. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-center trial. Q J Med 1994;87:75-81.
15. Murray HW. Interferon-γ and host antimicrobial defense: current and future clinical applications. Am J Med 1994;97:459-65.